Association of Brain Metastases With Immune Checkpoint Inhibitors Efficacy in Advanced Lung Cancer: A Systematic Review and Meta-Analysis

Bibliographic Details
Title: Association of Brain Metastases With Immune Checkpoint Inhibitors Efficacy in Advanced Lung Cancer: A Systematic Review and Meta-Analysis
Authors: Yanning Wang, Qianning Zhang, Chuansheng Chen, Yuxuan Hu, Liyun Miao, Yujie Zhou
Source: Frontiers in Oncology, Vol 11 (2021)
Publisher Information: Frontiers Media S.A., 2021.
Publication Year: 2021
Collection: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Subject Terms: immune checkpoint inhibitors, survival, brain metastases, lung carcinoma, meta-analysis, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
More Details: BackgroundIn pivotal immunotherapy trials, the efficacy of immune checkpoint inhibitors as treatments for lung cancer patients with brain metastases remains controversial. The aim of this study was to assess the relative efficacy of immunotherapy versus standard systemic therapy in advanced lung cancer patients with and without brain metastases.MethodsSystematic searches of PubMed, Embase, Cochrane database, and conference proceedings up to Aug 6, 2020 without year and language restrictions. The main outcomes were the overall survival in patients with and without brain metastases measured by hazard ratios, and the difference in efficacy between patients with and without brain metastases was measured by ratio of hazard ratios.ResultsNine eligible randomized controlled trials involving 6241 patients (682 [11%] with brain metastases and 5559 [89%] without brain metastases) were included in the analysis. A survival benefit of immunotherapy was observed for both patients with brain metastases (HR, 0.75; 95%CI, 0.53-0.97; P = .026) and patients without brain metastases (HR, 0.75; 95%CI, 0.67-0.83; P
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2234-943X
Relation: https://www.frontiersin.org/articles/10.3389/fonc.2021.721760/full; https://doaj.org/toc/2234-943X
DOI: 10.3389/fonc.2021.721760
Access URL: https://doaj.org/article/eb53586b220242fd88fd389f602b2153
Accession Number: edsdoj.b53586b220242fd88fd389f602b2153
Database: Directory of Open Access Journals
More Details
ISSN:2234943X
DOI:10.3389/fonc.2021.721760
Published in:Frontiers in Oncology
Language:English